Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) CEO Mark Pruzanski sold 10,000 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $230.60, for a total transaction of $2,306,000.00. Following the transaction, the chief executive officer now directly owns 470,174 shares of the company’s stock, valued at approximately $108,422,124. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on ICPT shares. Analysts at Summer Street initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, May 15th. They set a “buy” rating and a $650.00 price target on the stock. Separately, analysts at Oppenheimer cut their price target on shares of Intercept Pharmaceuticals from $525.00 to $499.00 in a research note on Thursday, May 8th. They now have an “outperform” rating on the stock. Finally, analysts at Needham & Company LLC reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $585.67.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 11.28% during mid-day trading on Wednesday, hitting $260.01. The stock had a trading volume of 789,361 shares. Intercept Pharmaceuticals has a 1-year low of $30.73 and a 1-year high of $497.00. The stock has a 50-day moving average of $251.4 and a 200-day moving average of $250.4. The company’s market cap is $5.483 billion. Intercept Pharmaceuticals also saw a large increase in short interest in May. As of May 15th, there was short interest totalling 740,868 shares, an increase of 34.0% from the April 30th total of 553,089 shares. Based on an average trading volume of 383,148 shares, the days-to-cover ratio is currently 1.9 days. Approximately 5.7% of the shares of the company are short sold.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, May 7th. The company reported ($1.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-13.40 earnings per share for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.